The Pharma Letter1h
$60 million AstraZeneca milestone payment for Eccogene
Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is ...
The Pharma Letter11h
Ocuphire buys Opus Genetics, grows gene therapy pipeline
Ocuphire Pharma (Nasdaq: OCUP) has announced the acquisition of Opus Genetics, a clinical-stage gene therapy company focused ...
The Pharma Letter11h
Ipsen posts strong third quarter results, raises outlook
Ipsen has reported strong Q3 2024 results, with sales reaching 837 million euros ($884 million), an 8.6% year-on-year ...
The Pharma Letter22h
New FDA approval for Pfizer’s RSV vaccine Abrysvo
The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and ...
The Pharma Letter19h
Second Alzheimer’s drug, donanemab, rejected for NHS use
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...
The Pharma Letter14h
Merck & Co buys Modifi Biosciences
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co (NYSE ...
The Pharma Letter21h
AvenCell raises $112 million in Series B financing
US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was ...
The Pharma Letter22h
Sangamo shares jump as FDA clears faster gene therapy pathway
Shares in Sangamo Therapeutics (Nasdaq: SGMO) surged around 40% on Tuesday, following the announcement that the US Food and ...
The Pharma Letter21h
Roche’s strong sales growth continues
Swiss pharma giant Roche this morning reported that, in the first nine months of 2024 group sales increased by 6% at CER (2% ...